Literature DB >> 23997524

Clinical diagnosis and treatment of alpha-fetoprotein-negative small hepatic lesions.

Yiyao Xu1, Xin Lu, Yilei Mao, Xinting Sang, Haitao Zhao, Shunda Du, Haifeng Xu, Yongliang Sun, Huayu Yang, Tianyi Chi, Zhiying Yang, Shouxian Zhong, Jiefu Huang.   

Abstract

OBJECTIVE: We examined 103 cases over the last five years and discussed diagnosis and treatment of alpha-fetoprotein (AFP)-negative small hepatic lesions.
BACKGROUND: Small hepatic lesions (less than 2 cm in diameter) usually have no typical imaging characteristics and therefore are difficult to diagnose, especially when AFP tests provide a negative result.
METHODS: A total of 103 patients with AFP-negative small hepatic lesions from January 2003 to December 2008 were retrospectively reviewed. Differential diagnosis was performed by digital subtraction angiography (DSA), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), contrast-enhanced ultrasound (CEUS), or positron emission tomography-computed tomography (PET-CT) based on the multiplicity of lesions. Ninety-four patients with suspected cancers underwent partial hepatectomy. Clinical data were collected from hospital records and follow-up questionnaires.
RESULTS: Hepatocellular carcinoma (HCC) diagnostic sensitivity of DSA, DCE-MRI, CEUS and PET-CT was 88.2%, 93.9%, 88.9% and 88.9%, respectively. The surgery-related complication rate was 6.4%. Prognosis was good, with 1- and 3-year survival rates of 98.8% and 76.1%, respectively.
CONCLUSIONS: DSA, DCE-MRI, CEUS and PET-CT are valuable for diagnosis of small hepatic lesions. Partial hepatectomy is a preferred surgical procedure. Surgery for small liver cancers usually has little risk and good prognosis, therefore it can be actively applied in suspected HCC cases.

Entities:  

Keywords:  Alpha-fetoprotein (AFP)-negative small hepatic lesions; contrast-enhanced ultrasound (CEUS); dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI); hepatectomy

Year:  2013        PMID: 23997524      PMCID: PMC3752356          DOI: 10.3978/j.issn.1000-9604.2013.08.12

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  16 in total

Review 1.  Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view.

Authors:  Masamichi Kojiro
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

2.  Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.

Authors:  Ryosuke Tateishi; Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Yukihiro Koike; Tomonori Fujishima; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

3.  Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma.

Authors:  Yilei Mao; Huayu Yang; Haifeng Xu; Xin Lu; Xinting Sang; Shunda Du; Haitao Zhao; Wang Chen; Yiyao Xu; Tianyi Chi; Zhiying Yang; Jianqiang Cai; Hui Li; Jianguo Chen; Shouxian Zhong; Smruti R Mohanti; Reynold Lopez-Soler; J Michael Millis; Jiefu Huang; Hongbing Zhang
Journal:  Gut       Date:  2010-09-28       Impact factor: 23.059

Review 4.  Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Fabio Piscaglia; Luigi Bolondi
Journal:  J Hepatol       Date:  2008-02-27       Impact factor: 25.083

5.  DKK1 as a serum biomarker for hepatocellular carcinoma.

Authors:  Peter A Prieto; Charles H Cha
Journal:  Hepatobiliary Surg Nutr       Date:  2013-06       Impact factor: 7.293

6.  Comparison of high-intensity focused ultrasound therapy and radiofrequency ablation for recurrent hepatocellular carcinoma.

Authors:  Hiroki Nishikawa; Yukio Osaki
Journal:  Hepatobiliary Surg Nutr       Date:  2013-06       Impact factor: 7.293

7.  GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.

Authors:  Jorge A Marrero; Patrick R Romano; Olga Nikolaeva; Laura Steel; Anand Mehta; Claus J Fimmel; Mary Ann Comunale; Anthony D'Amelio; Anna S Lok; Timothy M Block
Journal:  J Hepatol       Date:  2005-06-28       Impact factor: 25.083

8.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

9.  Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study.

Authors:  E Caturelli; L Solmi; M Anti; S Fusilli; P Roselli; A Andriulli; F Fornari; C Del Vecchio Blanco; I de Sio
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

10.  Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.

Authors:  Shinichi Ueno; Masahiko Sakoda; Fumitake Kubo; Kiyokazu Hiwatashi; Taro Tateno; Yoshiro Baba; Susumu Hasegawa; Hirohito Tsubouchi
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-03-20
View more
  2 in total

Review 1.  Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Agostino Colli; Vanja Giljaca; Mirella Fraquelli; Giovanni Casazza; Cristina Manzotti; Davor Štimac; Damir Miletic
Journal:  Cochrane Database Syst Rev       Date:  2022-05-06

2.  Clinical value of contrast-enhanced ultrasound in early diagnosis of small hepatocellular carcinoma (≤ 2 cm).

Authors:  Qi Mei; Mei Yu; Qiong Chen
Journal:  World J Clin Cases       Date:  2022-08-26       Impact factor: 1.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.